Nightsong
Senior Member (Voting Rights)
Surprisingly, MEA have commented on this:
This paper, from a group of health researchers at various universities, relates to fibromyalgia. However, it includes some critical comments about the way in which the MEA highlights very poor recovery rates as an important reason for raising money to carry out biomedical research into finding the cause/s of ME/CFS along with safe and effective forms of treatment that are targeted at the underlying disease process. We make no apologies for doing so and we do not agree that proving accurate information about poor recovery rates for ME/CFS inhibits patient recovery.
https://meassociation.org.uk/2025/0...ery-programmes-to-the-regulatory-authorities/The paper states that the money we raise for research is ‘almost exclusively' spent on pharmaceutical research. This is not correct. The vast majority of our research funding is spent on research relating to diagnostic biomarkers, causative factors – including post mortem research – and all the basic running costs of the ME Biobank. We do occasionally fund clinical trials into drug treatment, including the current LDN trial. But this only represents a very small proportion of our research expenditure over the years.